Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing LossGlobeNewsWire • 05/22/26
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain AmyloidosisGlobeNewsWire • 05/21/26
Levi & Korsinsky Announces Investigation of Securities Claims Against Regeneron Pharmaceuticals, Inc. (REGN)GlobeNewsWire • 05/21/26
REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities FraudBusiness Wire • 05/20/26
Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2BZacks Investment Research • 05/19/26
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?Zacks Investment Research • 05/19/26
REGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticals for Possible Securities Law ViolationsPRNewsWire • 05/19/26
Regeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN)PRNewsWire • 05/18/26
Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Contact Levi & Korsinsky About Fraud InvestigationNewsfile Corp • 05/18/26
Regeneron faces Wall Street downgrades after high-profile melanoma drug fails to beat Merck's KeytrudaProactive Investors • 05/18/26
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic AreasGlobeNewsWire • 05/18/26
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic AreasBusiness Wire • 05/18/26
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic MelanomaGlobeNewsWire • 05/16/26
UPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering FairGlobeNewsWire • 05/15/26
Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering FairGlobeNewsWire • 05/15/26
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/12/26
Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive YearsGlobeNewsWire • 05/08/26
Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 TrialGlobeNewsWire • 05/05/26